In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002
about
Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone.What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010.Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.Evaluation of the Do Bugs Need Drugs? program in British Columbia: Can we curb antibiotic prescribing?Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniaePrevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in KoreaAntimicrobial resistance - Judicious use is the keyGlobal fluoroquinolone resistance epidemiology and implictions for clinical use.Management of acute otitis media in children six months of age and olderTreating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?Antibiotic choices by paediatric residents and recently graduated paediatricians for typical infectious disease problems in children.Use of azithromycin in the treatment of acute exacerbations of COPD.Streptococcus pneumoniae infection: a Canadian perspective.Serotyping, Antibiotic Susceptibility and Related Risk Factors Aspects of Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy School Students.Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.In vitro activities of levofloxacin and comparable agents against middle ear fluid, nasopharyngeal, and oropharyngeal pathogens obtained from Costa Rican children with recurrent otitis media or failing other antibiotic therapyThe treatment of acute bacterial sinusitis: no change is good medicineSerotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007.La prise en charge de l’otite moyenne aiguë chez les enfants de six mois et plus.Pneumonia Due to Drug-Resistant Streptococcus pneumoniae.
P2860
Q33577091-DC65FA7F-7DF3-4EBB-AAEF-12CC7B42FEC1Q33856590-BEC04FCA-94FE-4BB2-810A-E4AC3AEE15A1Q34436045-0A3C3476-6DDC-4734-B333-69FE3828ED47Q34680540-2FCF23C4-9A73-45A1-B722-A3E9A549B4B0Q34789786-A7D781AC-27F1-4F89-88F2-E6FC900103C9Q35139545-87E11B86-F09B-4474-8BE8-AC72CA4A62DBQ35647682-44E6E0E3-9CAC-4929-80B7-7F774A84B17CQ35879084-CB8E07FA-2AC2-4F3A-8824-25E802A50DF2Q36170892-35444449-4C11-4B53-85DD-7E1116AB48E2Q36337074-40D2CEA5-0187-47E4-93CA-27B156FE383DQ36592918-FB31C655-5E71-49E6-8B97-A75D4479097FQ36728602-442DE6B3-8EB1-4074-9EB2-795C82C9EF9CQ36860431-AD940C65-3D5C-4AD7-8288-C371A7F5AFD6Q37115885-D87E1079-75B7-4C25-B04B-38A353C17D16Q38131534-CB23E8FC-A754-4C8D-B27D-921967718124Q38984686-8162066A-1379-41E6-9F5F-4DE3762E0EDDQ41854694-E5FE36C7-8575-47A1-B322-5665C5EFC2A5Q42071585-1B6A8386-E017-4C74-828E-4C87755B7004Q42098440-8D27129B-80DD-46A1-8C76-AEAE3CB0ECD6Q42112138-B3310EE5-23C2-4F0F-8FDF-562B7A7B3477Q42112713-D40BB246-E00D-44A0-8F11-8245D2D67B3AQ42789542-0AE170B1-61C4-4B48-9CE0-B1DB3430C80AQ46913156-3E8EDDFC-C4BF-48BD-8C79-3C530482F45BQ50953294-98A71AA6-B768-47CD-A9AD-EB6EFA595EF6
P2860
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro antimicrobial suscept ...... tes obtained in Canada in 2002
@en
In vitro antimicrobial suscept ...... es obtained in Canada in 2002.
@nl
type
label
In vitro antimicrobial suscept ...... tes obtained in Canada in 2002
@en
In vitro antimicrobial suscept ...... es obtained in Canada in 2002.
@nl
prefLabel
In vitro antimicrobial suscept ...... tes obtained in Canada in 2002
@en
In vitro antimicrobial suscept ...... es obtained in Canada in 2002.
@nl
P2093
P2860
P50
P1476
In vitro antimicrobial suscept ...... tes obtained in Canada in 2002
@en
P2093
Andrew Simor
Canadian Bacterial Surveillance Network
Daryl Hoban
Deirdre Church
Donald E Low
Karen Green
Karl Weiss
Kevin Forward
Magdalena Kuhn
Otto Vanderkooi
P2860
P304
P356
10.1128/AAC.48.9.3305-3311.2004
P407
P577
2004-09-01T00:00:00Z